Applications

Below is an example of a project conducted on the GAIA platform:

•  Evaluation of the biodistribution and therapeutic efficacy of NeoB  

  This study was carried out in collaboration with Advanced Accelerator Applications (a Novartis Company). Its objective was to evaluate NeoB, a novel theranostic agent targeting the gastrin-releasing peptide receptor (GRPR), in a mouse model bearing human gastrointestinal tumors. 

  NeoB was radiolabeled with Lu-177. Biodistribution was assessed from day 0 to day 7 post-injection using SPECT imaging and gamma counting, while therapeutic efficacy was monitored by tracking tumor volume over a 100-day period. 
  
  The results demonstrated high and sustained accumulation of Lu-177-NeoB in the tumors, with minimal uptake in non-target organs. Treatment led to tumor regression, complete in some cases, and significantly improved survival in treated animals.
  (Cancers 2021, 13, 1051. https://doi.org/10.3390/cancers13051051)